Malika Ammam,  —

Malika Ammam received her MS degree from the University of Pierre et Marie CURIE in July 2002 and her PhD from the University of Paris Sud XI, France in September 2005. From 2006 to 2007, she worked as a research fellow at the University of Kansas in collaboration with Pinnacle Technology Inc. (USA). From 2007 to 2010, she was a research associate at KU Leuven, Belgium. From 2010 to 2012, she worked at the University of Ontario Institute of Technology in collaboration with Alcohol Countermeasure Systems Corporation, Canada. She held a prestigious Rosalind Franklin fellowship and resigned in 2015. Now, she is a freelancer.

Articles by Malika Ammam

Phase III Trials Reveal That IPF Patients Treated Continually with ESBRIET for Long-term Have Reduced Risk of Death

Results from phase III trials with Esbriet® (pirfenidone), a drug developed by Roche, were recently presented at the European Respiratory Society (ERS) congress held in Amsterdam from September 26-30, 2015. The results revealed that Esbriet® is beneficial for long-term treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is characterized by progressive…

Data on Reata’s Experimental PAH Therapy to be Presented at CHEST Conference.

Reata Pharmaceuticals recently announced that results of a Phase 2 study of bardoxolone methyl in patients suffering from pulmonary arterial hypertension (PAH) will be presented at the 2015 American College of Chest Physicians (CHEST) annual meeting at the Palais des Congrès de Montréal, Canada. The presentation, entitled “Initial Data Report from…